Living with non-radiographic axial SpA (nr-AxSpA) or ankylosing spondylitis (AS) can come with a lot of questions, especially when it comes to choosing the right treatment.
In this episode of Meet the Maker, rheumatologists Dr. Atul Deodhar and Dr. Jeffrey Stark discuss the medication BIMZELX® (bimekizumab-bkzx). They explain how it works, how it’s different from other treatments, and what patients have experienced in clinical trials. The video also includes information on common side effects, how the medication is taken, and the support resources UCB provides, such as nurse navigators and financial assistance.
Watch the video below to learn more about this treatment option and support program.
A detailed document for healthcare professionals that includes full prescribing guidelines, dosage information, and clinical data.
An easy-to-read guide for patients, covering how to take BIMZELX safely, potential side effects, and important things to discuss with a doctor.
The official site for BIMZELX® offers information about how the medication works, who it’s for, and what to expect during treatment.
UCB is the global biopharmaceutical company behind BIMZELX, with a focus on developing innovative treatments for chronic neurological and inflammatory conditions.
Meet the Maker is an educational video series from the Spondylitis Association of America that gives patients a closer look at the medications used to treat spondyloarthritis. Each episode features conversations with both medical experts and representatives from the companies that develop these treatments.
The goal is to help patients better understand how a medication works, what kind of results they might expect, and what support is available, so they can make informed decisions with their health care providers.
Input your search keywords and press Enter.
